论文部分内容阅读
目的探讨异丙托溴铵联合β受体激动剂吸入治疗慢性阻塞性肺疾病(COPD)急性加重期的临床疗效。方法选取2012年6月—2014年6月在抚州市高新产业园区崇岗镇卫生院就诊的COPD急性加重期患者90例,按随机数表法将患者分为观察组与对照组,各45例。对照组患者给予常规治疗,观察组患者在常规治疗基础上予以异丙托溴铵联合β受体激动剂吸入治疗。观察两组患者临床评分、第1秒用力呼气容积(FEV1)、第1秒用力呼气容积占用力肺活量百分比(FEV1/FVC)、呼吸峰值流速(PEFR)及不良反应情况。结果治疗前两组患者临床评分比较,差异无统计学意义(P>0.05),治疗后观察组患者临床评分低于对照组,差异有统计学意义(P<0.05);治疗前两组患者FEV1、FEV1/FVC及PEFR比较,差异无统计学意义(P>0.05),治疗后观察组患者FEV1、FEV1/FVC及PEFR高于对照组(P<0.05);治疗期间两组患者均未出现严重不良反应。结论异丙托溴铵联合β受体激动剂吸入治疗COPD急性加重期的临床疗效确切,能明显改善患者的临床症状及肺功能,不良反应少。
Objective To investigate the clinical efficacy of ipratropium bromide combined with β-agonist inhalation in the treatment of acute exacerbation of chronic obstructive pulmonary disease (COPD). Methods Ninety patients with acute exacerbation of COPD were selected from June 2012 to June 2014 in Chonggang Town Hospital of Fuzhou High-tech Industrial Park. According to the random number table, the patients were divided into observation group and control group, with 45 cases in each group . Patients in the control group were given routine treatment. Patients in the observation group were treated with ipratropium bromide and β-agonist inhalation on the basis of routine treatment. The clinical scores, FEV1, FEV1 / FVC, PEFR and adverse reactions of the two groups were observed. Results There was no significant difference in clinical scores between the two groups before treatment (P> 0.05). After treatment, the clinical scores of the observation group were lower than those of the control group (P <0.05). Before treatment, FEV1 , FEV1 / FVC and PEFR, the difference was not statistically significant (P> 0.05). After treatment, the FEV1, FEV1 / FVC and PEFR in the observation group were higher than those in the control group (P <0.05) Adverse reactions. Conclusion Ipratropium bromide combined with β-agonist inhalation for the treatment of acute exacerbation of COPD has definite curative effect, which can significantly improve the clinical symptoms and pulmonary function of patients with less adverse reactions.